Acquired Gene or Chromosome Alterations Pipeline by Development Stages, Segments, Countries, Regulatory Path and Key Companies

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Acquired Gene or Chromosome Alterations Pipeline Market Report Overview

Acquired Gene or Chromosome Alterations are reagents employed for genetic testing to detect cancer-causing or related alterations. The Acquired Gene or Chromosome Alterations pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials.

Key Territories ·        The US

·        Europe

·        Canada

·        India

·        China

Key Regulatory Paths ·        510(k)

·        CE-IVD

·        PMA

·        ICAC

·        MDL

Leading Companies ·        Abital Pharma Pipelines Ltd

·        Admera Health LLC

·        Agena Bioscience Inc

·        Aix-Marseille University

·        Albert Ludwigs University of Freiburg

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Acquired Gene or Chromosome Alterations Pipeline Market Segmentation by Territories

A few of the key territories for acquired gene or chromosome alterations pipeline products are the US, Europe, Canada, India, and China. As of December 2023, the US accounted for the highest number of pipeline products.

Acquired Gene or Chromosome Alterations Pipeline Market Analysis by Territories, 2023 (%)

Acquired Gene or Chromosome Alterations Pipeline Market Analysis by Territories, 2023 (%)

Buy the Full Report for More Territory Insights into the Acquired Gene or Chromosome Alterations Pipeline Market

Download a Free Report Sample

Acquired Gene or Chromosome Alterations Pipeline Market Segmentation by Regulatory Paths

A few of the key regulatory paths followed by the acquired gene or chromosome alterations pipeline market are 510(k), CE-IVD, PMA, ICAC, and MDL. As of December 2023, 510(k) was the most followed pathway for pipeline products in the market.

Acquired Gene or Chromosome Alterations Pipeline Market Analysis by Regulatory Paths, 2023 (%)

Acquired Gene or Chromosome Alterations Pipeline Market Analysis by Regulatory Paths, 2023 (%)

Buy the Full Report for More Regulatory Path Insights into the Acquired Gene or Chromosome Alterations Pipeline Market

Download a Free Report Sample

Acquired Gene or Chromosome Alterations Pipeline Market – Competitive Landscape

A few of the key companies associated with the acquired gene or chromosome alterations pipeline market are Abital Pharma Pipelines Ltd, Admera Health LLC, Agena Bioscience Inc., Aix-Marseille University, Albert Ludwigs University of Freiburg, among others.

Admera Health LLC: Admera Health is headquartered in South Plainfield, New Jersey, the US. It also operates in New York, Florida, Maryland, Pennsylvania, and Rhode Island, the US. Admera is a molecular diagnostics company that focuses on personalized medicine, non-invasive cancer testing, and digital health. It also provides physician-ordered DNA tests.

Agena Bioscience Inc: Agena Bioscience is headquartered in San Diego, California, the US. It operates as a medical device company with offices in Germany, China, Japan, and Australia. Agena Bioscience’s products are also used for genotyping and mutation detection, ultrasensitive detection, methylation analysis, oncology, and other applications. The company exports its products through a network of distributors globally.

Acquired Gene or Chromosome Alterations Pipeline Market Analysis by Companies, 2023

Acquired Gene or Chromosome Alterations Pipeline Market Analysis by Companies, 2023

Buy the Full Report for More Company Insights into the Acquired Gene or Chromosome Alterations Pipeline Market

Download a Free Report Sample

Segments Covered in the Report

Acquired Gene or Chromosome Alterations Pipeline Market Territories Outlook

  • The US
  • Europe
  • Canada
  • India
  • China

Acquired Gene or Chromosome Alterations Pipeline Market Regulatory Paths Outlook

  • 510(k)
  • CE-IVD
  • PMA
  • ICAC
  • MDL

Scope

This report provides:

  • Extensive coverage of the Acquired Gene or Chromosome Alterations under development.
  • Exhaustive list of major pipeline products and their details, including product description, licensing and collaboration details, and other developmental activities.
  • Reviews of major players involved in the development of acquired gene or chromosome alterations and lists all their pipeline projects.
  • Coverage of pipeline products based on various stages of development ranging from early development to approved/issued stage.
  • Key clinical trial data of ongoing clinical trials specific to pipeline products.
  • Recent developments in the segment/industry.

Reasons to Buy

The report will enable you to:

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
  • Identify and understand important and diverse types of acquired gene or chromosome alterations under development.
  • Develop market-entry and market-expansion strategies.
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline.
  • Carry out in-depth analysis of the product’s current stage of development, territory, and estimated launch date.

Abital Pharma Pipelines Ltd
Admera Health LLC
Agena Bioscience Inc
Aix-Marseille University
Albert Ludwigs University of Freiburg
Apteryx Imaging Inc
Baruch S. Blumberg Institute
Baylor College of Medicine
bioMerieux SA
Biotype Innovation GmbH
Blondin Bioscience, LLC
Cardiff Oncology Inc
Cepheid Inc
Children's Hospital Los Angeles
Children's Hospital of Philadelphia
China Medical Technologies Inc (Inactive)
Chronix Biomedical Inc
Columbia University
Duke University
Empire Genomics LLC
Fred Hutchinson Cancer Research Center
French National Institute of Health and Medical Research
Garvan Institute of Medical Research
Gencurix Inc
Genetag Technology, Inc
Genomic Health Inc
GenomicTree Co Ltd
German Cancer Research Center
H. Lee Moffitt Cancer Center & Research Institute Inc
Heali Ltd
Hebrew University of Jerusalem
Heidelberg Pharma AG
Helmholtz Centre for Infection Research
Inform Genomics Inc
Institute of Cancer Research
Interpace Biosciences Inc
iTP Biomedica Corp
Johns Hopkins University
Massachusetts General Hospital
Mayo Clinic
McGill University
MDNA Life Sciences Inc
MolecularMD Corp
Myriad International GmbH
Nel ASA
Northern California Institute for Research and Education
NucleoBio Inc
Ohio State University
OmicsWay Corp
Oxford Biodynamics Plc
Oxford Cancer Biomarkers Ltd
Pennsylvania State University
Princess Margaret Cancer Centre
QuantuMDx Group Ltd
Queen's University Belfast
Rosetta Genomics Ltd (Inactive)
Stanford University
Stony Brook University
Syamala Srinivasa Life Sciences Pvt. Ltd
Telo Genomics Corp
The Chinese University of Hong Kong
The University of New South Wales press Limited
The Walter and Eliza Hall Institute of Medical Research
TheraDiag SA
Therawis Diagnostics GmbH
Thrive Earlier Detection Corp
Total Brain Ltd
Trinity College Dublin
University College London
University of California San Diego
University of Cambridge
University of Central Florida
University of Cologne
University of Copenhagen
University of Hawaii at Manoa
University of Montreal
University of Rochester
University of South Carolina
University of Southern California
University of Strathclyde
University of Sydney
University of Texas Medical Branch at Galveston
University of Washington
Vyant Bio Inc
Wistar Institute
Yaathum Biotech Pvt Ltd
Yale University

Table of Contents

|1 Table of Contents 3

|1.1 List of Tables 9

|1.2 List of Figures 17

2 Introduction 18

2.1 Acquired Gene or Chromosome Alterations Overview 18

3 Products under Development 19

3.1 Acquired Gene or Chromosome Alterations – Pipeline Products by Stage of Development 19

3.2 Acquired Gene or Chromosome Alterations – Pipeline Products by Territory 20

3.3 Acquired Gene or Chromosome Alterations – Pipeline Products by Regulatory Path 21

3.4 Acquired Gene or Chromosome Alterations – Pipeline Products by Estimated Approval Date 22

3.5 Acquired Gene or Chromosome Alterations – Ongoing Clinical Trials 23

4 Acquired Gene or Chromosome Alterations – Pipeline Products under Development by Companies 24

4.1 Acquired Gene or Chromosome Alterations Companies – Pipeline Products by Stage of Development 24

4.2 Acquired Gene or Chromosome Alterations – Pipeline Products by Stage of Development 28

5 Acquired Gene or Chromosome Alterations Companies and Product Overview 33

5.1 Abital Pharma Pipelines Ltd Company Overview 33

5.1.1 Abital Pharma Pipelines Ltd Pipeline Products & Ongoing Clinical Trials Overview 33

5.2 Admera Health LLC Company Overview 34

5.2.1 Admera Health LLC Pipeline Products & Ongoing Clinical Trials Overview 34

5.3 Agena Bioscience Inc Company Overview 37

5.3.1 Agena Bioscience Inc Pipeline Products & Ongoing Clinical Trials Overview 37

5.4 Aix-Marseille University Company Overview 38

5.4.1 Aix-Marseille University Pipeline Products & Ongoing Clinical Trials Overview 38

5.5 Albert Ludwigs University of Freiburg Company Overview 39

5.5.1 Albert Ludwigs University of Freiburg Pipeline Products & Ongoing Clinical Trials Overview 39

5.6 Apteryx Imaging Inc Company Overview 40

5.6.1 Apteryx Imaging Inc Pipeline Products & Ongoing Clinical Trials Overview 40

5.7 Baruch S. Blumberg Institute Company Overview 41

5.7.1 Baruch S. Blumberg Institute Pipeline Products & Ongoing Clinical Trials Overview 41

5.8 Baylor College of Medicine Company Overview 42

5.8.1 Baylor College of Medicine Pipeline Products & Ongoing Clinical Trials Overview 42

5.9 bioMerieux SA Company Overview 44

5.9.1 bioMerieux SA Pipeline Products & Ongoing Clinical Trials Overview 44

5.10 Biotype Innovation GmbH Company Overview 45

5.10.1 Biotype Innovation GmbH Pipeline Products & Ongoing Clinical Trials Overview 45

5.11 Blondin Bioscience, LLC Company Overview 47

5.11.1 Blondin Bioscience, LLC Pipeline Products & Ongoing Clinical Trials Overview 47

5.12 Cardiff Oncology Inc Company Overview 50

5.12.1 Cardiff Oncology Inc Pipeline Products & Ongoing Clinical Trials Overview 50

5.13 Cepheid Inc Company Overview 51

5.13.1 Cepheid Inc Pipeline Products & Ongoing Clinical Trials Overview 51

5.14 Children’s Hospital Los Angeles Company Overview 52

5.14.1 Children’s Hospital Los Angeles Pipeline Products & Ongoing Clinical Trials Overview 52

5.15 Children’s Hospital of Philadelphia Company Overview 53

5.15.1 Children’s Hospital of Philadelphia Pipeline Products & Ongoing Clinical Trials Overview 53

5.16 China Medical Technologies Inc (Inactive) Company Overview 54

5.16.1 China Medical Technologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 54

5.17 Chronix Biomedical Inc Company Overview 55

5.17.1 Chronix Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 55

5.18 Columbia University Company Overview 56

5.18.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview 56

5.19 Duke University Company Overview 59

5.19.1 Duke University Pipeline Products & Ongoing Clinical Trials Overview 59

5.20 Empire Genomics LLC Company Overview 60

5.20.1 Empire Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 60

5.21 Fred Hutchinson Cancer Research Center Company Overview 61

5.21.1 Fred Hutchinson Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 61

5.22 French National Institute of Health and Medical Research Company Overview 72

5.22.1 French National Institute of Health and Medical Research Pipeline Products & Ongoing Clinical Trials Overview 72

5.23 Garvan Institute of Medical Research Company Overview 73

5.23.1 Garvan Institute of Medical Research Pipeline Products & Ongoing Clinical Trials Overview 73

5.24 Gencurix Inc Company Overview 75

5.24.1 Gencurix Inc Pipeline Products & Ongoing Clinical Trials Overview 75

5.25 Genetag Technology, Inc Company Overview 76

5.25.1 Genetag Technology, Inc Pipeline Products & Ongoing Clinical Trials Overview 76

5.26 Genomic Health Inc Company Overview 78

5.26.1 Genomic Health Inc Pipeline Products & Ongoing Clinical Trials Overview 78

5.27 GenomicTree Co Ltd Company Overview 80

5.27.1 GenomicTree Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 80

5.28 German Cancer Research Center Company Overview 81

5.28.1 German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 81

5.29 H. Lee Moffitt Cancer Center & Research Institute Inc Company Overview 83

5.29.1 H. Lee Moffitt Cancer Center & Research Institute Inc Pipeline Products & Ongoing Clinical Trials Overview 83

5.30 Heali Ltd Company Overview 93

5.30.1 Heali Ltd Pipeline Products & Ongoing Clinical Trials Overview 93

5.31 Hebrew University of Jerusalem Company Overview 94

5.31.1 Hebrew University of Jerusalem Pipeline Products & Ongoing Clinical Trials Overview 94

5.32 Heidelberg Pharma AG Company Overview 95

5.32.1 Heidelberg Pharma AG Pipeline Products & Ongoing Clinical Trials Overview 95

5.33 Helmholtz Centre for Infection Research Company Overview 96

5.33.1 Helmholtz Centre for Infection Research Pipeline Products & Ongoing Clinical Trials Overview 96

5.34 Inform Genomics Inc Company Overview 98

5.34.1 Inform Genomics Inc Pipeline Products & Ongoing Clinical Trials Overview 98

5.35 Institute of Cancer Research Company Overview 99

5.35.1 Institute of Cancer Research Pipeline Products & Ongoing Clinical Trials Overview 99

5.36 Interpace Biosciences Inc Company Overview 101

5.36.1 Interpace Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 101

5.37 iTP Biomedica Corp Company Overview 104

5.37.1 iTP Biomedica Corp Pipeline Products & Ongoing Clinical Trials Overview 104

5.38 Johns Hopkins University Company Overview 105

5.38.1 Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 105

5.39 Massachusetts General Hospital Company Overview 120

5.39.1 Massachusetts General Hospital Pipeline Products & Ongoing Clinical Trials Overview 120

5.40 Mayo Clinic Company Overview 121

5.40.1 Mayo Clinic Pipeline Products & Ongoing Clinical Trials Overview 121

5.41 McGill University Company Overview 124

5.41.1 McGill University Pipeline Products & Ongoing Clinical Trials Overview 124

5.42 MDNA Life Sciences Inc Company Overview 125

5.42.1 MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 125

5.43 MolecularMD Corp Company Overview 126

5.43.1 MolecularMD Corp Pipeline Products & Ongoing Clinical Trials Overview 126

5.44 Myriad International GmbH Company Overview 128

5.44.1 Myriad International GmbH Pipeline Products & Ongoing Clinical Trials Overview 128

5.45 Nel ASA Company Overview 129

5.45.1 Nel ASA Pipeline Products & Ongoing Clinical Trials Overview 129

5.46 Northern California Institute for Research and Education Company Overview 130

5.46.1 Northern California Institute for Research and Education Pipeline Products & Ongoing Clinical Trials Overview 130

5.47 NucleoBio Inc Company Overview 131

5.47.1 NucleoBio Inc Pipeline Products & Ongoing Clinical Trials Overview 131

5.48 Ohio State University Company Overview 132

5.48.1 Ohio State University Pipeline Products & Ongoing Clinical Trials Overview 132

5.49 OmicsWay Corp Company Overview 133

5.49.1 OmicsWay Corp Pipeline Products & Ongoing Clinical Trials Overview 133

5.50 Oxford Biodynamics Plc Company Overview 134

5.50.1 Oxford Biodynamics Plc Pipeline Products & Ongoing Clinical Trials Overview 134

5.51 Oxford Cancer Biomarkers Ltd Company Overview 136

5.51.1 Oxford Cancer Biomarkers Ltd Pipeline Products & Ongoing Clinical Trials Overview 136

5.52 Pennsylvania State University Company Overview 137

5.52.1 Pennsylvania State University Pipeline Products & Ongoing Clinical Trials Overview 137

5.53 Princess Margaret Cancer Centre Company Overview 138

5.53.1 Princess Margaret Cancer Centre Pipeline Products & Ongoing Clinical Trials Overview 138

5.54 QuantuMDx Group Ltd Company Overview 139

5.54.1 QuantuMDx Group Ltd Pipeline Products & Ongoing Clinical Trials Overview 139

5.55 Queen’s University Belfast Company Overview 140

5.55.1 Queen’s University Belfast Pipeline Products & Ongoing Clinical Trials Overview 140

5.56 Rosetta Genomics Ltd (Inactive) Company Overview 141

5.56.1 Rosetta Genomics Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 141

5.57 Stanford University Company Overview 142

5.57.1 Stanford University Pipeline Products & Ongoing Clinical Trials Overview 142

5.58 Stony Brook University Company Overview 144

5.58.1 Stony Brook University Pipeline Products & Ongoing Clinical Trials Overview 144

5.59 Syamala Srinivasa Life Sciences Pvt. Ltd Company Overview 145

5.59.1 Syamala Srinivasa Life Sciences Pvt. Ltd Pipeline Products & Ongoing Clinical Trials Overview 145

5.60 Telo Genomics Corp Company Overview 147

5.60.1 Telo Genomics Corp Pipeline Products & Ongoing Clinical Trials Overview 147

5.61 The Chinese University of Hong Kong Company Overview 151

5.61.1 The Chinese University of Hong Kong Pipeline Products & Ongoing Clinical Trials Overview 151

5.62 The University of New South Wales press Limited Company Overview 153

5.62.1 The University of New South Wales press Limited Pipeline Products & Ongoing Clinical Trials Overview 153

5.63 The Walter and Eliza Hall Institute of Medical Research Company Overview 154

5.63.1 The Walter and Eliza Hall Institute of Medical Research Pipeline Products & Ongoing Clinical Trials Overview 154

5.64 TheraDiag SA Company Overview 158

5.64.1 TheraDiag SA Pipeline Products & Ongoing Clinical Trials Overview 158

5.65 Therawis Diagnostics GmbH Company Overview 163

5.65.1 Therawis Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview 163

5.66 Thrive Earlier Detection Corp Company Overview 164

5.66.1 Thrive Earlier Detection Corp Pipeline Products & Ongoing Clinical Trials Overview 164

5.67 Total Brain Ltd Company Overview 165

5.67.1 Total Brain Ltd Pipeline Products & Ongoing Clinical Trials Overview 165

5.68 Trinity College Dublin Company Overview 166

5.68.1 Trinity College Dublin Pipeline Products & Ongoing Clinical Trials Overview 166

5.69 University College London Company Overview 167

5.69.1 University College London Pipeline Products & Ongoing Clinical Trials Overview 167

5.70 University of California San Diego Company Overview 168

5.70.1 University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview 168

5.71 University of Cambridge Company Overview 169

5.71.1 University of Cambridge Pipeline Products & Ongoing Clinical Trials Overview 169

5.72 University of Central Florida Company Overview 171

5.72.1 University of Central Florida Pipeline Products & Ongoing Clinical Trials Overview 171

5.73 University of Cologne Company Overview 172

5.73.1 University of Cologne Pipeline Products & Ongoing Clinical Trials Overview 172

5.74 University of Copenhagen Company Overview 173

5.74.1 University of Copenhagen Pipeline Products & Ongoing Clinical Trials Overview 173

5.75 University of Hawaii at Manoa Company Overview 174

5.75.1 University of Hawaii at Manoa Pipeline Products & Ongoing Clinical Trials Overview 174

5.76 University of Montreal Company Overview 175

5.76.1 University of Montreal Pipeline Products & Ongoing Clinical Trials Overview 175

5.77 University of Rochester Company Overview 177

5.77.1 University of Rochester Pipeline Products & Ongoing Clinical Trials Overview 177

5.78 University of South Carolina Company Overview 178

5.78.1 University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview 178

5.79 University of Southern California Company Overview 179

5.79.1 University of Southern California Pipeline Products & Ongoing Clinical Trials Overview 179

5.80 University of Strathclyde Company Overview 181

5.80.1 University of Strathclyde Pipeline Products & Ongoing Clinical Trials Overview 181

5.81 University of Sydney Company Overview 182

5.81.1 University of Sydney Pipeline Products & Ongoing Clinical Trials Overview 182

5.82 University of Texas Medical Branch at Galveston Company Overview 183

5.82.1 University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview 183

5.83 University of Washington Company Overview 184

5.83.1 University of Washington Pipeline Products & Ongoing Clinical Trials Overview 184

5.84 Vyant Bio Inc Company Overview 185

5.84.1 Vyant Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 185

5.85 Wistar Institute Company Overview 186

5.85.1 Wistar Institute Pipeline Products & Ongoing Clinical Trials Overview 186

5.86 Yaathum Biotech Pvt Ltd Company Overview 187

5.86.1 Yaathum Biotech Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 187

5.87 Yale University Company Overview 188

5.87.1 Yale University Pipeline Products & Ongoing Clinical Trials Overview 188

6 Acquired Gene or Chromosome Alterations- Recent Developments 189

6.1 Dec 13, 2023: Pfizer Provides Full-Year 2024 Guidance 189

6.2 Dec 12, 2023: Genentech Announces Appointment of Ashley Magargee as Chief Executive Officer 192

6.3 Dec 10, 2023: MGI Expands Presence in Latin America with New Partnerships with Genos Médica and TCL Group 193

6.4 Nov 20, 2023: Labcorp and Legacy Health Finalize Comprehensive Laboratory Relationship 194

6.5 Nov 14, 2023: Genomic Vision: Financial Information for the Third Quarter of 2023 194

6.6 Nov 07, 2023: SOPHiA GENETICS Reports Financial Results for the Third Quarter of Fiscal 2023 Record results on growth acceleration, significant improvement in operating loss and cash burn 195

6.7 Nov 03, 2023: Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx-UM That Could Aid in the Early Detection of Uveal Melanomas 195

6.8 Nov 02, 2023: Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update 196

6.9 Oct 31, 2023: Amgen Reports Third Quarter Financial Results 198

6.10 Oct 28, 2023: Pfizer Q2 Results: Drug Maker’s Profit Declines 52% To Rs 149 Crore 200

6.11 Oct 27, 2023: ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023 200

6.12 Oct 26, 2023: Labcorp Announces 2023 Third Quarter Results 202

6.13 Oct 26, 2023: Lilly to Participate in UBS Biopharma Conference 2023 205

6.14 Oct 20, 2023: Lilly Confirms Date and Conference Call for Third-Quarter 2023 Financial Results Announcement 205

6.15 Oct 19, 2023: bioMérieux Makes Strategic Investment in Oxford Nanopore 206

6.16 Oct 06, 2023: Children’s Mercy Kansas City First to Use 5-Base HiFi Genomic Sequencing in the Clinical Setting 207

6.17 Oct 05, 2023: Illumina to Announce Third Quarter 2023 Financial Results on Thursday, November 9, 2023 208

6.18 Oct 04, 2023: Lilly Announces Leadership Transitions 208

6.19 Oct 04, 2023: AbbVie to Host Third-Quarter 2023 Earnings Conference Call 209

6.20 Sep 29, 2023: Genomic Vision: First-Half 2023 Results 209

6.21 Sep 28, 2023: Pfizer Appoints New Chief IR Officer 210

6.22 Sep 27, 2023: Mdxhealth Signs Research Collaboration with University of Oxford to Assess the Correlation of the GPS Test with Prostate Cancer Progression Following Treatment for Localized Prostate Cancer 210

6.23 Sep 14, 2023: Labcorp to Present Strategy, Business and Financial Outlook at Investor Day 211

6.24 Sep 07, 2023: Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s Tests 211

6.25 Sep 05, 2023: Illumina’s Board Appoints Jacob Thaysen, Ph.D. as its New Chief Executive Officer 212

6.26 Aug 28, 2023: Novartis to Let Go 100 Employees in Latest Round of Layoffs 212

6.27 Aug 17, 2023: Myriad Genetics to Host Investor Day on September 19, 2023 212

6.28 Aug 17, 2023: Illumina Expands Genomics Capabilities in India with Opening of Solutions Center 213

6.29 Aug 17, 2023: Illumina Announces Lays Off 151 San Diego workers 214

6.30 Aug 13, 2023: Illumina Announces Departure of Chief Medical Officer and Chief Technology Officer 214

6.31 Aug 09, 2023: Cigna Expands Commercial and Medicare Advantage Coverage to Include Mdxhealth’s Select mdx for Prostate Cancer Test 214

6.32 Aug 09, 2023: Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results 214

6.33 Aug 09, 2023: Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update 215

6.34 Aug 09, 2023: Dr. Steven Barnard Appointed Chief Technology Officer 216

6.35 Aug 08, 2023: Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update 217

6.36 Aug 01, 2023: Astellas Pharma Announces Results for the First Three Months of FY2023 219

6.37 Jul 31, 2023: Labcorp to Host Investor Day on September 14, 2023 220

6.38 Jul 10, 2023: Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN Reimbursement 220

6.39 Jul 03, 2023: Pacific Edge Updates Billing Policies for US Testing 221

6.40 Jun 30, 2023: Centogene Announces Approval of All Resolutions Tabled at 2023 Annual General Meeting 221

6.41 Jun 29, 2023: NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors 222

6.42 Jun 27, 2023: bioMErieux’s Executive Committee evolves: Jennifer Zinn appointed Executive Vice President of Clinical Operations 222

6.43 Jun 15, 2023: Amgen lures Moderna Exec to be its Chief Medical Officer 222

6.44 Jun 07, 2023: Genomic Vision Provides Strategy Update 222

6.45 Jun 05, 2023: Biocartis Announces Resignation CFO 224

6.46 Jun 03, 2023: Castle Biosciences to share new data on DecisionDx®=-Melanoma and DecisionDx-UM at the 2023 ASCO Annual Meeting 224

6.47 Jun 02, 2023: Illumina’s Board of Directors elects two experienced Independent Directors to Board 224

6.48 Jun 02, 2023: Agilent Intelligent Mass Spectrometry Solutions to Inspire at ASMS 2023 225

6.49 May 29, 2023: Invivoscribe receives updated reimbursement for LeukoStrat assay in Japan 226

6.50 May 16, 2023: CENTOGENE reports full year 2022 financial results 227

6.51 May 16, 2023: Oxford BioDynamics notice of interim results and investor webinar 228

6.52 May 12, 2023: Invivoscribe’s LeukoStrat assay receives IVDR approval 229

6.53 May 12, 2023: Biocartis Group announces results of the annual shareholders meeting held on 12 May 2023 229

6.54 May 09, 2023: Natera reports first quarter 2023 financial results 229

6.55 May 08, 2023: NeoGenomics reports first quarter 2023 results 232

6.56 May 04, 2023: Celldex reports First Quarter 2023 financial results and provides corporate update 233

6.57 May 04, 2023: Cardiff Oncology reports first-quarter 2023 results and provides business update 236

6.58 May 03, 2023: Myriad Genetics reports first quarter 2023 financial results 237

6.59 Apr 27, 2023: AMGEN reports first quarter financial results 239

6.60 Apr 27, 2023: Veracyte announces five abstracts providing molecular insights into prostate and other cancers to be presented at the 2023 ASCO Annual Meeting 241

6.61 Apr 25, 2023: Illumina reports financial results for first quarter of fiscal year 2023; announces commitment to accelerate margin growth 243

6.62 Apr 20, 2023: QIAGEN announces expansion of supervisory board 245

6.63 Apr 19, 2023: Foundational LCD covers select mdx for prostate cancer 245

6.64 Apr 19, 2023: Foundation Medicine lays off 135 employees 246

6.65 Apr 13, 2023: Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results 246

6.66 Apr 11, 2023: Biocartis appoints Roger Moody as new CEO 246

6.67 Mar 31, 2023: Pacific Edge provides update on Kaiser EMR integration 247

6.68 Mar 28, 2023: EKF Diagnostics Holdings Announces its final results for the year ended 31 December 2022 248

6.69 Mar 15, 2023: Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 249

6.70 Mar 10, 2023: GSK publishes Annual Report 2022 249

6.71 Mar 09, 2023: CENTOGENE Appoints Ian Rentsch as Chief Commercial Officer and General Manager 250

6.72 Mar 08, 2023: bioMerieux Announces 2022 Financial Results for the year ending December 31, 2022 250

6.73 Feb 28, 2023: Genomic Vision Financial Information for the Fourth Quarter of 2022 251

6.74 Feb 27, 2023: Musa Tariq Joins Guardant Health Board of Directors 252

6.75 Feb 27, 2023: Daan Gene’s Prelim 2022 Net Profit Up

53.1% Y/Y 252

6.76 Feb 23, 2023: Biocartis announces 2022 results and 2023 outlook 252

6.77 Feb 23, 2023: Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors 258

6.78 Feb 16, 2023: Labcorp Announces 2022 Fourth Quarter and Full-Year Results 258

6.79 Feb 16, 2023: Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors 261

6.80 Feb 13, 2023: MDxHealth announces UnitedHealthcare to provide commercial coverage for the genomic Prostate Score (GPS) Test 261

6.81 Feb 09, 2023: Sysmex Announces Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2023 262

6.82 Feb 09, 2023: Pfizer Announces Appointment of Meenakshi Nevatia as the Managing Director 264

6.83 Feb 08, 2023: Sysmex Corp. Notice of Changes in Representative Directors 264

6.84 Feb 08, 2023: Astellas Pharma Announces Financial Results Third quarter FY2022 265

6.85 Feb 07, 2023: QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups 266

6.86 Feb 01, 2023: Novartis Announces Annual Report 2022 267

6.87 Feb 01, 2023: Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023 268

6.88 Jan 31, 2023: Daiichi Sankyo Announces Consolidated Financial Results for the First Nine Months of the Year Ending March 31,2023 268

6.89 Jan 25, 2023: Guardant Health Lays off 7 Percent of Workforce 270

6.90 Jan 20, 2023: Quest Diagnostics to Release Fourth Quarter and Full Year 2022 Financial Results on February 2, 2023 270

6.91 Jan 19, 2023: Lilly Confirms Date and Conference Call for Fourth-Quarter 2022 Financial Results 271

6.92 Jan 19, 2023: Bioasis Announces Filing of its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2022 271

6.93 Jan 17, 2023: Data presentations at 2023 Winter Clinical Dermatology Conference – Hawaii support clinical value of Castle Biosciences’ skin cancer test portfolio 271

6.94 Jan 09, 2023: Guardant Health Announces Preliminary Fourth Quarter and Full Year 2022 Results 273

6.95 Dec 28, 2022: Centogene Announces Its Attendance at the 41st Annual J.P. Morgan Healthcare Meeting and Fierce JPM Week in San Francisco 274

6.96 Dec 22, 2022: CENTOGENE Reports Second Quarter and First Half 2022 Financial Results 274

7 Appendix 280

7.1 Methodology 280

7.2 About GlobalData 283

7.3 Contact Us 283

7.4 Disclaimer 283

Table

Acquired Gene or Chromosome Alterations – Pipeline Products by Stage of Development 19

Acquired Gene or Chromosome Alterations – Pipeline Products by Territory 20

Acquired Gene or Chromosome Alterations – Pipeline Products by Regulatory Path 21

Acquired Gene or Chromosome Alterations – Pipeline Products by Estimated Approval Date 22

Acquired Gene or Chromosome Alterations – Ongoing Clinical Trials 23

Acquired Gene or Chromosome Alterations Companies – Pipeline Products by Stage of Development 24

Acquired Gene or Chromosome Alterations – Pipeline Products by Stage of Development 28

Abital Pharma Pipelines Ltd Pipeline Products & Ongoing Clinical Trials Overview 33

Diagnostic Assay – Parkinson’s Disease – Product Status 33

Diagnostic Assay – Parkinson’s Disease – Product Description 33

Admera Health LLC Pipeline Products & Ongoing Clinical Trials Overview 34

Diagnostic Test – Prostate Cancer – Product Status 34

Diagnostic Test – Prostate Cancer – Product Description 34

OncoGxOne Plus – Product Status 35

OncoGxOne Plus – Product Description 35

Pan-Cancer Test – Product Status 35

Pan-Cancer Test – Product Description 36

Agena Bioscience Inc Pipeline Products & Ongoing Clinical Trials Overview 37

MassARRAY System – Companion Diagnostic Assay – Product Status 37

MassARRAY System – Companion Diagnostic Assay – Product Description 37

Aix-Marseille University Pipeline Products & Ongoing Clinical Trials Overview 38

Companion Diagnostic Assay – T-Cell Acute Lymphoblastic Leukemia – Product Status 38

Companion Diagnostic Assay – T-Cell Acute Lymphoblastic Leukemia – Product Description 38

Albert Ludwigs University of Freiburg Pipeline Products & Ongoing Clinical Trials Overview 39

Molecular Assay – Neoplasias and Solid Tumors – Product Status 39

Molecular Assay – Neoplasias and Solid Tumors – Product Description 39

Apteryx Imaging Inc Pipeline Products & Ongoing Clinical Trials Overview 40

Oral Cancer Progression – Risk Assessment Test – Product Status 40

Oral Cancer Progression – Risk Assessment Test – Product Description 40

Baruch S. Blumberg Institute Pipeline Products & Ongoing Clinical Trials Overview 41

Cell-Free DNA Assay – Product Status 41

Cell-Free DNA Assay – Product Description 41

Baylor College of Medicine Pipeline Products & Ongoing Clinical Trials Overview 42

Diagnostic Assay Assay – Ovarian Cancer – Product Status 42

Diagnostic Assay Assay – Ovarian Cancer – Product Description 42

Noninvasive Diagnostic Test – Colorectal Cancer – Product Status 43

Noninvasive Diagnostic Test – Colorectal Cancer – Product Description 43

bioMerieux SA Pipeline Products & Ongoing Clinical Trials Overview 44

BRAF – Breast Cancer Diagnostic Kit – Product Status 44

BRAF – Breast Cancer Diagnostic Kit – Product Description 44

Biotype Innovation GmbH Pipeline Products & Ongoing Clinical Trials Overview 45

Modaplex KRAS Mutation Analysis Kit – Product Status 45

Modaplex KRAS Mutation Analysis Kit – Product Description 45

Modaplex NRAS Mutation Analysis Kit – Product Status 46

Modaplex NRAS Mutation Analysis Kit – Product Description 46

Blondin Bioscience, LLC Pipeline Products & Ongoing Clinical Trials Overview 47

FACT Assay – Metastatic Colon Cancer – Product Status 47

FACT Assay – Metastatic Colon Cancer – Product Description 47

FACT Assay – Metastatic Non-small Cell Lung Cancer – Product Status 48

FACT Assay – Metastatic Non-small Cell Lung Cancer – Product Description 48

FACT Assay – Triple Negative Breast Cancer – Product Status 48

FACT Assay – Triple Negative Breast Cancer – Product Description 49

Cardiff Oncology Inc Pipeline Products & Ongoing Clinical Trials Overview 50

Diagnostic Assay – HBV – Product Status 50

Diagnostic Assay – HBV – Product Description 50

Cepheid Inc Pipeline Products & Ongoing Clinical Trials Overview 51

Urine Based Screening Test – Cervical Cancer – Product Status 51

Urine Based Screening Test – Cervical Cancer – Product Description 51

Children’s Hospital Los Angeles Pipeline Products & Ongoing Clinical Trials Overview 52

Neuroblastoma Biomarker Assay – Product Status 52

Neuroblastoma Biomarker Assay – Product Description 52

Children’s Hospital of Philadelphia Pipeline Products & Ongoing Clinical Trials Overview 53

Diagnostic Assay – Epithelial Tumors – Product Status 53

Diagnostic Assay – Epithelial Tumors – Product Description 53

China Medical Technologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 54

FISH Diagnostic Test – Lymphoma – Product Status 54

FISH Diagnostic Test – Lymphoma – Product Description 54

Chronix Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 55

Companion Diagnostic Test – Colorectal Cancer – Product Status 55

Companion Diagnostic Test – Colorectal Cancer – Product Description 55

Columbia University Pipeline Products & Ongoing Clinical Trials Overview 56

anti-PD-1 Immunotherapy Resistance Prediction Test – Product Status 56

anti-PD-1 Immunotherapy Resistance Prediction Test – Product Description 56

Biomarker Panel Test – Skin Cancer – Product Status 57

Biomarker Panel Test – Skin Cancer – Product Description 57

Diagnostic Test – Multiple Myeloma – Product Status 57

Diagnostic Test – Multiple Myeloma – Product Description 58

Duke University Pipeline Products & Ongoing Clinical Trials Overview 59

Diagnostic Test – Follicular Thyroid Adenoma/Carcinoma – Product Status 59

Diagnostic Test – Follicular Thyroid Adenoma/Carcinoma – Product Description 59

Empire Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 60

Companion Diagnostic Test – Neuroendocrine Prostate Cancer – Product Status 60

Companion Diagnostic Test – Neuroendocrine Prostate Cancer – Product Description 60

Fred Hutchinson Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 61

ATP7A Gene-Based Immuno-MRM Assay – Product Status 61

ATP7A Gene-Based Immuno-MRM Assay – Product Description 62

BARD1 Gene-Based Immuno-MRM assay – Product Status 62

BARD1 Gene-Based Immuno-MRM assay – Product Description 62

BCL2 Gene-Based Immuno-MRM assay – Product Status 63

BCL2 Gene-Based Immuno-MRM assay – Product Description 63

BCL2L1 Gene-Based Immuno-MRM Assay – Product Status 63

BCL2L1 Gene-Based Immuno-MRM Assay – Product Description 64

C20orf30 Gene Based IMAC MRM Assay – Cancer – Product Status 64

C20orf30 Gene Based IMAC MRM Assay – Cancer – Product Description 64

Diagnostic Test – Oral Cancer – Product Status 65

Diagnostic Test – Oral Cancer – Product Description 65

ERCC5 Gene-Based Immuno-MRM Assay – Product Status 65

ERCC5 Gene-Based Immuno-MRM Assay – Product Description 66

MAD2L2 Gene-Based Immuno-MRM Assay – Product Status 66

MAD2L2 Gene-Based Immuno-MRM Assay – Product Description 66

MYBBP1A Gene Based IMAC MRM Assay – Cancer – Product Status 67

MYBBP1A Gene Based IMAC MRM Assay – Cancer – Product Description 67

MYO9B Gene Based IMAC MRM Assay – Cancer – Product Status 67

MYO9B Gene Based IMAC MRM Assay – Cancer – Product Description 67

NBEAL2 Gene Based IMAC MRM Assay – Cancer – Product Status 68

NBEAL2 Gene Based IMAC MRM Assay – Cancer – Product Description 68

NCL Gene Based IMAC MRM Assay – Cancer – Product Status 68

NCL Gene Based IMAC MRM Assay – Cancer – Product Description 68

NFATC1 Gene Based IMAC MRM Assay – Cancer – Product Status 69

NFATC1 Gene Based IMAC MRM Assay – Cancer – Product Description 69

NSUN2 Gene Based IMAC MRM Assay – Cancer – Product Status 69

NSUN2 Gene Based IMAC MRM Assay – Cancer – Product Description 69

NUFIP2 Gene Based IMAC MRM Assay – Cancer – Product Status 70

NUFIP2 Gene Based IMAC MRM Assay – Cancer – Product Description 70

NUMA1 Gene Based IMAC MRM Assay – Cancer – Product Status 70

NUMA1 Gene Based IMAC MRM Assay – Cancer – Product Description 70

NUP107 Gene Based IMAC MRM Assay – Cancer – Product Status 71

NUP107 Gene Based IMAC MRM Assay – Cancer – Product Description 71

French National Institute of Health and Medical Research Pipeline Products & Ongoing Clinical Trials Overview 72

Biomarker Based Assay – Pancreatic Cancer – Product Status 72

Biomarker Based Assay – Pancreatic Cancer – Product Description 72

Garvan Institute of Medical Research Pipeline Products & Ongoing Clinical Trials Overview 73

Diagnostic Test – Blood Cancer – Product Status 73

Diagnostic Test – Blood Cancer – Product Description 73

Diagnostic Test- Solid Tumors – Product Status 74

Diagnostic Test- Solid Tumors – Product Description 74

Gencurix Inc Pipeline Products & Ongoing Clinical Trials Overview 75

GenesWell CDx CCT – Product Status 75

GenesWell CDx CCT – Product Description 75

Genetag Technology, Inc Pipeline Products & Ongoing Clinical Trials Overview 76

Blood-Based Assay – Product Status 76

Blood-Based Assay – Product Description 76

DDS Probe – HBV/HCV – Product Status 77

DDS Probe – HBV/HCV – Product Description 77

Genomic Health Inc Pipeline Products & Ongoing Clinical Trials Overview 78

Diagnostic Test – Non Small Cell Lung Cancer – Product Status 78

Diagnostic Test – Non Small Cell Lung Cancer – Product Description 78

Oncotype SEQ – Tissue Mutation Panel – Product Status 79

Oncotype SEQ – Tissue Mutation Panel – Product Description 79

GenomicTree Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 80

AccuraTect EGFR – Product Status 80

AccuraTect EGFR – Product Description 80

German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 81

BCAT1 Based Diagnosis Assay – Brain Tumor – Product Status 81

BCAT1 Based Diagnosis Assay – Brain Tumor – Product Description 81

Prognostic Assay – Bladder Cancer – Product Status 82

Prognostic Assay – Bladder Cancer – Product Description 82

H. Lee Moffitt Cancer Center & Research Institute Inc Pipeline Products & Ongoing Clinical Trials Overview 83

Biomarker Assay – Programmed Death Protein-1 Blockade Immunotherapy – Product Status 83

Biomarker Assay – Programmed Death Protein-1 Blockade Immunotherapy – Product Description 84

Biomarker Based Diagnostic Assay – CTLA-4 Blockade Immunotherapy – Product Status 84

Biomarker Based Diagnostic Assay – CTLA-4 Blockade Immunotherapy – Product Description 84

Companion Diagnostic – Immunotherapy Response Prediction – Product Status 85

Companion Diagnostic – Immunotherapy Response Prediction – Product Description 85

CREB (cAMP Response Element-Binding Protein) Gene Signature Based Assay – Ovarian Cancer – Product Status 85

CREB (cAMP Response Element-Binding Protein) Gene Signature Based Assay – Ovarian Cancer – Product Description 86

Diagnostic Assay – Lung Cancer – Product Status 86

Diagnostic Assay – Lung Cancer – Product Description 86

Diagnostic Assay – Metastatic Melanoma – Product Status 87

Diagnostic Assay – Metastatic Melanoma – Product Description 87

Gene Polymorphism Based Assay – Prostate Cancer Recurrence – Product Status 87

Gene Polymorphism Based Assay – Prostate Cancer Recurrence – Product Description 88

Gene Signature Based Assay – Gliomas – Product Status 88

Gene Signature Based Assay – Gliomas – Product Description 88

Genetic Test – Tumor Sensitivity To Radiation Therapy – Product Status 89

Genetic Test – Tumor Sensitivity To Radiation Therapy – Product Description 89

Immune-related Gene Signature Assay – Cancer – Product Status 89

Immune-related Gene Signature Assay – Cancer – Product Description 90

Immunotherapy Response Prediction Test – Product Status 90

Immunotherapy Response Prediction Test – Product Description 90

NanoString Assay – NSCLC – Product Status 91

NanoString Assay – NSCLC – Product Description 91

NF-KB Based Gene Signature Assay – Cancer – Product Status 91

NF-KB Based Gene Signature Assay – Cancer – Product Description 92

O-Glycan Gene Signature Assay – Ovarian Cancer – Product Status 92

O-Glycan Gene Signature Assay – Ovarian Cancer – Product Description 92

Heali Ltd Pipeline Products & Ongoing Clinical Trials Overview 93

ONCOASSAY Breast – Product Status 93

ONCOASSAY Breast – Product Description 93

Hebrew University of Jerusalem Pipeline Products & Ongoing Clinical Trials Overview 94

MicroRNA Based Assay – Osteosarcoma – Product Status 94

MicroRNA Based Assay – Osteosarcoma – Product Description 94

Heidelberg Pharma AG Pipeline Products & Ongoing Clinical Trials Overview 95

TP53/RNA Companion Diagnostic Assay – Product Status 95

TP53/RNA Companion Diagnostic Assay – Product Description 95

Helmholtz Centre for Infection Research Pipeline Products & Ongoing Clinical Trials Overview 96

Genetic Biomarker – Androgenetic Alopecia – Product Status 96

Genetic Biomarker – Androgenetic Alopecia – Product Description 97

Inform Genomics Inc Pipeline Products & Ongoing Clinical Trials Overview 98

HSCT – Product Status 98

HSCT – Product Description 98

Institute of Cancer Research Pipeline Products & Ongoing Clinical Trials Overview 99

Liquid Biopsy Test – Product Status 99

Liquid Biopsy Test – Product Description 99

Saliva Based Test – Prostate Cancer – Product Status 100

Saliva Based Test – Prostate Cancer – Product Description 100

Interpace Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 101

Diagnostic Assay – Biliary Cancer – Product Status 101

Diagnostic Assay – Biliary Cancer – Product Description 101

PancraMir – Product Status 102

PancraMir – Product Description 102

PathFinderTG MvP Dx – Product Status 102

PathFinderTG MvP Dx – Product Description 103

iTP Biomedica Corp Pipeline Products & Ongoing Clinical Trials Overview 104

Prognostic Test – Kidney Fibrosis – Product Status 104

Prognostic Test – Kidney Fibrosis – Product Description 104

Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 105

Anti-Cancer Drug Based Assay – Product Status 106

Anti-Cancer Drug Based Assay – Product Description 106

Biomarker Assay – Metastatic Prostate Cancer – Product Status 106

Biomarker Assay – Metastatic Prostate Cancer – Product Description 107

BRCA2 Diagnostic Assay – Product Status 107

BRCA2 Diagnostic Assay – Product Description 107

CpG Hypermethylated Gene Assay – Colorectal Cancer – Product Status 108

CpG Hypermethylated Gene Assay – Colorectal Cancer – Product Description 108

Diagnosis Assay – Esophageal Cancer – Product Status 108

Diagnosis Assay – Esophageal Cancer – Product Description 109

Diagnostic And Prognostic Biomarker Assay – Thyroid Cancer – Product Status 109

Diagnostic And Prognostic Biomarker Assay – Thyroid Cancer – Product Description 109

Diagnostic Assay – ESCC – Product Status 110

Diagnostic Assay – ESCC – Product Description 110

Diagnostic Assay – Sturge-Weber Syndrome – Product Status 110

Diagnostic Assay – Sturge-Weber Syndrome – Product Description 111

Diagnostic Kit – Pancreatic Neuroendrocrine Tumor – Product Status 111

Diagnostic Kit – Pancreatic Neuroendrocrine Tumor – Product Description 111

Diagnostic Test – Brain Cancer – Product Status 112

Diagnostic Test – Brain Cancer – Product Description 112

Epigenetic Diagnostic Assay – Gastric Cancer – Product Status 112

Epigenetic Diagnostic Assay – Gastric Cancer – Product Description 113

Epigenetically Silenced Gene Assay – Colon Cancer – Product Status 113

Epigenetically Silenced Gene Assay – Colon Cancer – Product Description 113

Epigenetically Silenced Gene Assay – Gastric Cancer – Product Status 114

Epigenetically Silenced Gene Assay – Gastric Cancer – Product Description 114

Gene Based Biomarker Assay – Thyroid Cancer – Product Status 114

Gene Based Biomarker Assay – Thyroid Cancer – Product Description 115

GSTP1 Hypermethylation Assay – Product Status 115

GSTP1 Hypermethylation Assay – Product Description 115

HEYL Oncogene Test – Product Status 116

HEYL Oncogene Test – Product Description 116

HOXB13 Biomarker Test – Prostate Cancer – Product Status 116

HOXB13 Biomarker Test – Prostate Cancer – Product Description 117

Methyl-BEAMing Assay – Product Status 117

Methyl-BEAMing Assay – Product Description 117

Molecular Diagnostic Assay – Aggressive Brain Tumor – Product Status 118

Molecular Diagnostic Assay – Aggressive Brain Tumor – Product Description 118

Prognostic Assay – Breast Cancer – Product Status 118

Prognostic Assay – Breast Cancer – Product Description 119

Massachusetts General Hospital Pipeline Products & Ongoing Clinical Trials Overview 120

Blood-Companion Diagnostic Assay – Glioblastoma – Product Status 120

Blood-Companion Diagnostic Assay – Glioblastoma – Product Description 120

Mayo Clinic Pipeline Products & Ongoing Clinical Trials Overview 121

Colorectal Cancer Risk Assessment Test – Product Status 121

Colorectal Cancer Risk Assessment Test – Product Description 121

Diagnostic Test – Bladder Cancer – Product Status 122

Diagnostic Test – Bladder Cancer – Product Description 122

Genetic Test – Breast Cancer – Product Status 122

Genetic Test – Breast Cancer – Product Description 123

McGill University Pipeline Products & Ongoing Clinical Trials Overview 124

Diagnostic Test – Glioblastoma – Product Status 124

Diagnostic Test – Glioblastoma – Product Description 124

MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 125

Skin DNA Mitomic Test – Product Status 125

Skin DNA Mitomic Test – Product Description 125

MolecularMD Corp Pipeline Products & Ongoing Clinical Trials Overview 126

Companion Diagnostic Assay – Non-Small Cell Lung Cancer – Product Status 126

Companion Diagnostic Assay – Non-Small Cell Lung Cancer – Product Description 126

FGFR2 Mutation Assay – Product Status 127

FGFR2 Mutation Assay – Product Description 127

IHC Assay – Lung Cancer – Product Status 127

IHC Assay – Lung Cancer – Product Description 127

Myriad International GmbH Pipeline Products & Ongoing Clinical Trials Overview 128

ChemoPredict Test – Product Status 128

ChemoPredict Test – Product Description 128

Nel ASA Pipeline Products & Ongoing Clinical Trials Overview 129

PDtect – Product Status 129

PDtect – Product Description 129

Northern California Institute for Research and Education Pipeline Products & Ongoing Clinical Trials Overview 130

Biomarkers – Kidney Cancer – Product Status 130

Biomarkers – Kidney Cancer – Product Description 130

NucleoBio Inc Pipeline Products & Ongoing Clinical Trials Overview 131

Prostac – Product Status 131

Prostac – Product Description 131

Ohio State University Pipeline Products & Ongoing Clinical Trials Overview 132

Diagnostic Test – Lung Cancer – Product Status 132

Diagnostic Test – Lung Cancer – Product Description 132

OmicsWay Corp Pipeline Products & Ongoing Clinical Trials Overview 133

Oncobox:Sorafenib Test – Product Status 133

Oncobox:Sorafenib Test – Product Description 133

Oxford Biodynamics Plc Pipeline Products & Ongoing Clinical Trials Overview 134

EpiSwitch Nasopharyngeal Cancer Test – Product Status 134

EpiSwitch Nasopharyngeal Cancer Test – Product Description 134

EpiSwitch Prostate Cancer Prognostic Assay – Product Status 135

EpiSwitch Prostate Cancer Prognostic Assay – Product Description 135

Oxford Cancer Biomarkers Ltd Pipeline Products & Ongoing Clinical Trials Overview 136

ColoPredict – Product Status 136

ColoPredict – Product Description 136

Pennsylvania State University Pipeline Products & Ongoing Clinical Trials Overview 137

Lipid Nanoprobe Test – Product Status 137

Lipid Nanoprobe Test – Product Description 137

Princess Margaret Cancer Centre Pipeline Products & Ongoing Clinical Trials Overview 138

Screening Test – AML – Product Status 138

Screening Test – AML – Product Description 138

QuantuMDx Group Ltd Pipeline Products & Ongoing Clinical Trials Overview 139

Q-POC – EGFR NSCLC Assay – Product Status 139

Q-POC – EGFR NSCLC Assay – Product Description 139

Queen’s University Belfast Pipeline Products & Ongoing Clinical Trials Overview 140

Blood Based Assay – Cancer – Product Status 140

Blood Based Assay – Cancer – Product Description 140

Rosetta Genomics Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 141

RosettaGX Reveal – Second Version – Product Status 141

RosettaGX Reveal – Second Version – Product Description 141

Stanford University Pipeline Products & Ongoing Clinical Trials Overview 142

Biomarker Panel – Bladder Cancer – Product Status 142

Biomarker Panel – Bladder Cancer – Product Description 142

Screening Test – Post-Transplant Lymphoproliferative Disease – Product Status 143

Screening Test – Post-Transplant Lymphoproliferative Disease – Product Description 143

Stony Brook University Pipeline Products & Ongoing Clinical Trials Overview 144

Diagnostic Test – Colorectal Cancer – Product Status 144

Diagnostic Test – Colorectal Cancer – Product Description 144

Syamala Srinivasa Life Sciences Pvt. Ltd Pipeline Products & Ongoing Clinical Trials Overview 145

BRCA 1 & BRCA 2 Test Kit – Product Status 145

BRCA 1 & BRCA 2 Test Kit – Product Description 145

EGFR Mutational Analysis Kit – Product Status 146

EGFR Mutational Analysis Kit – Product Description 146

JAK2 Mutational Analysis Test Kit – Product Status 146

JAK2 Mutational Analysis Test Kit – Product Description 146

Telo Genomics Corp Pipeline Products & Ongoing Clinical Trials Overview 147

3D Telo-BC Test – Product Status 147

3D Telo-BC Test – Product Description 148

3D Telo-CE Test – Product Status 148

3D Telo-CE Test – Product Description 148

3D Telo-HL Test – Product Status 149

3D Telo-HL Test – Product Description 149

3D Telo-MM Test – Product Status 149

3D Telo-MM Test – Product Description 150

3D Telo-TC Test – Product Status 150

3D Telo-TC Test – Product Description 150

The Chinese University of Hong Kong Pipeline Products & Ongoing Clinical Trials Overview 151

Diagnostic Assay – Cataract – Product Status 151

Diagnostic Assay – Cataract – Product Description 151

Diagnostic Assay – Gastric Cancer – Product Status 152

Diagnostic Assay – Gastric Cancer – Product Description 152

Human Hepatocellular Carcinoma Diagnostic Kit – Product Status 152

Human Hepatocellular Carcinoma Diagnostic Kit – Product Description 152

The University of New South Wales press Limited Pipeline Products & Ongoing Clinical Trials Overview 153

Gold-Plated Nanoparticle Device – Cancer – Product Status 153

Gold-Plated Nanoparticle Device – Cancer – Product Description 153

The Walter and Eliza Hall Institute of Medical Research Pipeline Products & Ongoing Clinical Trials Overview 154

ctDNA Test – Ovarian Cancer – Product Status 154

ctDNA Test – Ovarian Cancer – Product Description 154

ctDNA Test – Pancreatic Cancer – Product Status 155

ctDNA Test – Pancreatic Cancer – Product Description 155

The Walter and Eliza Hall Institute of Medical Research – Ongoing Clinical Trials Overview 156

ctDNA Test – Ovarian Cancer – A Study to Evaluate the Use of Circulating Tumour DNA to Guide Adjuvant Chemotherapy on Recurrence-free Survival in Patients with Stage II Colon or Rectal Cancer 157

TheraDiag SA Pipeline Products & Ongoing Clinical Trials Overview 158

microRNA Prognostic Test – Ovarian Cancer – Product Status 158

microRNA Prognostic Test – Ovarian Cancer – Product Description 158

microRNA Theranostic Test – Autoimmune Disease – Product Status 159

microRNA Theranostic Test – Autoimmune Disease – Product Description 159

microRNA Theranostic Test – Colorectal Cancer – Product Status 159

microRNA Theranostic Test – Colorectal Cancer – Product Description 160

Tissue Messenger RNA Based Test – Rectal Cancer – Product Status 160

Tissue Messenger RNA Based Test – Rectal Cancer – Product Description 160

TheraDiag SA – Ongoing Clinical Trials Overview 161

microRNA Theranostic Test – Colorectal Cancer – microRNA Signature Predicting a Subject’s Therapeutic Response in Locally Advanced Rectal Cancer 162

Therawis Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview 163

EpiRespond-TN – Product Status 163

EpiRespond-TN – Product Description 163

Thrive Earlier Detection Corp Pipeline Products & Ongoing Clinical Trials Overview 164

UroSeqS – Product Status 164

UroSeqS – Product Description 164

Total Brain Ltd Pipeline Products & Ongoing Clinical Trials Overview 165

ADHD Treatment Test With Cognition Plus Selected Genomics – Product Status 165

ADHD Treatment Test With Cognition Plus Selected Genomics – Product Description 165

Trinity College Dublin Pipeline Products & Ongoing Clinical Trials Overview 166

Lungmark – Product Status 166

Lungmark – Product Description 166

University College London Pipeline Products & Ongoing Clinical Trials Overview 167

Genetic Profile Test – Lung Cancer – Product Status 167

Genetic Profile Test – Lung Cancer – Product Description 167

University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview 168

Biomarker Test – Chronic Myelogenous Leukemia (CML) Progression – Product Status 168

Biomarker Test – Chronic Myelogenous Leukemia (CML) Progression – Product Description 168

University of Cambridge Pipeline Products & Ongoing Clinical Trials Overview 169

Diagnostic Blood Test – Ovarian Cancer – Product Status 169

Diagnostic Blood Test – Ovarian Cancer – Product Description 169

Genetic Test – Oesophageal Cancer – Product Status 170

Genetic Test – Oesophageal Cancer – Product Description 170

University of Central Florida Pipeline Products & Ongoing Clinical Trials Overview 171

MKRN1 Biomarker Assay – Product Status 171

MKRN1 Biomarker Assay – Product Description 171

University of Cologne Pipeline Products & Ongoing Clinical Trials Overview 172

NRG1/CD74 Gene Fusion Test – Lung Cancer – Product Status 172

NRG1/CD74 Gene Fusion Test – Lung Cancer – Product Description 172

University of Copenhagen Pipeline Products & Ongoing Clinical Trials Overview 173

Diagnostic Blood Test – Pancreatic Cancer – Product Status 173

Diagnostic Blood Test – Pancreatic Cancer – Product Description 173

University of Hawaii at Manoa Pipeline Products & Ongoing Clinical Trials Overview 174

Companion Diagnostic Test – Breast Cancer – Product Status 174

Companion Diagnostic Test – Breast Cancer – Product Description 174

University of Montreal Pipeline Products & Ongoing Clinical Trials Overview 175

Genetic Biomarker Test – Ovarian Cancer – Product Status 175

Genetic Biomarker Test – Ovarian Cancer – Product Description 175

Prognostic Tool – Acute Myeloid Leukemia – Product Status 176

Prognostic Tool – Acute Myeloid Leukemia – Product Description 176

University of Rochester Pipeline Products & Ongoing Clinical Trials Overview 177

Diagnostic Test – Lymphoma – Product Status 177

Diagnostic Test – Lymphoma – Product Description 177

University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview 178

miR-489 Based Diagnostic Test – Breast Cancer – Product Status 178

miR-489 Based Diagnostic Test – Breast Cancer – Product Description 178

University of Southern California Pipeline Products & Ongoing Clinical Trials Overview 179

Blood Test – Metastatic breast cancer – Product Status 179

Blood Test – Metastatic breast cancer – Product Description 179

Gene Based Test – Colorectal Cancer – Product Status 180

Gene Based Test – Colorectal Cancer – Product Description 180

University of Strathclyde Pipeline Products & Ongoing Clinical Trials Overview 181

RNA-Nanoprobe – Lung Cancer – Product Status 181

RNA-Nanoprobe – Lung Cancer – Product Description 181

University of Sydney Pipeline Products & Ongoing Clinical Trials Overview 182

PROSPER-2 Genomic Test – Product Status 182

PROSPER-2 Genomic Test – Product Description 182

University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview 183

TSG 101 Based Diagnostic Assay – Product Status 183

TSG 101 Based Diagnostic Assay – Product Description 183

University of Washington Pipeline Products & Ongoing Clinical Trials Overview 184

Biomarker Assay – Colon Cancer – Product Status 184

Biomarker Assay – Colon Cancer – Product Description 184

Vyant Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 185

UroGenRA – Bladder – Product Status 185

UroGenRA – Bladder – Product Description 185

Wistar Institute Pipeline Products & Ongoing Clinical Trials Overview 186

29-Gene Signature Based Test – Lung Cancer – Product Status 186

29-Gene Signature Based Test – Lung Cancer – Product Description 186

Yaathum Biotech Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 187

Screening-Diagnostic-Prognostic Test – Thalassemia – Product Status 187

Screening-Diagnostic-Prognostic Test – Thalassemia – Product Description 187

Yale University Pipeline Products & Ongoing Clinical Trials Overview 188

Diagnostic Test – Prostate Cancer – Product Status 188

Diagnostic Test – Prostate Cancer – Product Description 188

Glossary 282

Figures

Acquired Gene or Chromosome Alterations – Pipeline Products by Stage of Development 19

Acquired Gene or Chromosome Alterations – Pipeline Products by Territory 20

Acquired Gene or Chromosome Alterations – Pipeline Products by Regulatory Path 21

Acquired Gene or Chromosome Alterations – Pipeline Products by Estimated Approval Date 22

Acquired Gene or Chromosome Alterations – Ongoing Clinical Trials 23

Frequently asked questions

Acquired Gene or Chromosome Alterations Pipeline by Development Stages, Segments, Countries, Regulatory Path and Key Companies thematic reports
Currency USD
$4,000

Can be used by individual purchaser only

$12,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Acquired Gene or Chromosome Alterations Pipeline by Development Stages, Segments, Countries, Regulatory Path and Key Companies was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Acquired Gene or Chromosome Alterations Pipeline by Development Stages, Segments, Countries, Regulatory Path and Key Companies in real time.

  • Access a live Acquired Gene or Chromosome Alterations Pipeline by Development Stages, Segments, Countries, Regulatory Path and Key Companies dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.